NCT05732974|Recruiting
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
MIRACLE
Loading search results
MIRACLE
Sponsor study identifier
observational
60
1 country
1
Study Start
March 30, 2023
Actual (reported)Primary Completion
November 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 14, 2022
Actual (reported)February 17, 2023
Actual (reported)March 30, 2023
Actual (reported)November 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Algorithm for disease free survival
Analysis on a training cohort of resected early-stage non small cell lung cancer
18 months
Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery
plasma sample, tissue sample and computed tomography scan images
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patient with an early stage of non small cell lung cancer with an indication of surgical resection
Julien MAZIERES
Toulouse, 31059, France
biomarkers detected on plasma and tissue samples for analysis of circulating and extracellular vesicles-derived microRNAs as well as of free circulating DNA performed
Julien MAZIERES, MD, PhD
University Hospital, Toulouse
First Submitted
November 14, 2022
First Posted
February 17, 2023
Study Start
March 30, 2023
Actual (reported)Primary Completion
November 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Contact the study team to confirm eligibility.
Study Completion
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
September 21, 2023
Record last verified: 2023-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: